SIRPA and neoplasm: These results indicate that SIRPα+ DCs were significantly more effective than SIRPα− DCs in inducing CD8 T cell proliferation and activation, providing a mechanistic link between expansion/activation of SIRPα+CD11c+ DCs and enhanced antitumor T cell responses in mice vaccinated with CD47-deficient tumor cells.